ArticleAmerican journal of human genetics1992
Cloning of a candidate gene for ataxia-telangiectasia group D.
Article in American journal of human genetics, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 101 citations in OpenAlex.
- TRIM29 upregulation contributes to chemoresistance in triple negative breast cancer via modulating S100P-β-catenin axis.Cell communication and signaling : CCS · 2025Article
- TRIM29 alters bioenergetics of pancreatic cancer cells via cooperation of miR-2355-3p and DDX3X recruitment to AK4 transcript.Molecular therapy. Nucleic acids · 2021Article
- ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer.Genes & development · 2021Article
- Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation.Oncogene · 2020Article
- ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis.Genes & development · 2019Article
- Prognostic value of tripartite motif containing 29 expression in patients with gastric cancer following surgical resection.Oncology letters · 2018Article
- TRIMming p53's anticancer activity.Oncogene · 2016Review
- Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway.Oncotarget · 2016Article
- TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin.Nature communications · 2015Article
- ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells.Cancer research · 2014Article
- Ataxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-κB pathway.PloS one · 2013Article
- TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.The American journal of pathology · 2012Article
- TRIM proteins and cancer.Nature reviews. Cancer · 2011Article
- The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions.Molecular and cellular biology · 2010Article
- The role of NBS1 in the modulation of PIKK family proteins ATM and ATR in the cellular response to DNA damage.Cancer letters · 2006Review
- HIT family genes: FHIT but not PKCI-1/HINT produces altered transcripts in colorectal cancer.British journal of cancer · 1999Article
- Development of the immune system.Infectious diseases in obstetrics and gynecology · 1997Article
- Measurement of DNA repair deficiency in workers exposed to benzene.Environmental health perspectives · 1996Article
- Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations.British journal of cancer · 1995Article
- The product of the ataxia-telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Transfection, with a human cosmid clone library, of an ataxia-telangiectasia (AT) cell line (AT5BIVA) from complementation group D previously resulted in the isolation of a cell line (1B3) with partially restored resistance to ionizing radiation. We rescued the integrated cosmid sequences within 1B3 and obtained two cosmid clones that contained overlapping DNA from chromosomal region 11q23, previously shown to be the region containing the AT gene(s) from three complementation groups. Isolation of an apparently full-length 3.0-kb cDNA from a HeLa cell library demonstrated a previously unidentified gene (ATDC) within these cosmid clones. The transfected copy of the ATDC gene in 1B3 is truncated at the 3' end but is a complete transcription unit, because of the presence of SV40 termination sequences within the adjacent cosmid DNA. After further screening of cosmid clones from a chromosome 11 library, we identified contiguous DNA that contained the missing portion of the gene. Southern blot analysis indicated that the ATDC gene is present in a single copy in the human genome; however, RNA blot analysis revealed mRNA of several sizes (1.8, 2.6, 3.0, 4.7, and 5.7 kb) that varied among different cell lines. Because no large rearrangements were detected in AT5BIVA cells by Southern or RNA blot analysis, any alteration in the ATDC gene in this cell line would involve a point mutation or a small rearrangement. Transfection of the AT5BIVA cell line with one of the cosmids partially restored radioresistance. Analysis of 100 X-radiation hybrid cell lines containing various fragments from the chromosomal region 11q23 showed that the ATDC gene is closely linked to THY1. The ATDC gene therefore lies outside the linkage region predicted to contain the AT gene(s) for complementation groups A and C, indicating a separate locus for the AT complementation group D gene.
Indexed as
Identifiers
1609804PMC1682873W1818914725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.